Clinical Trials & Research Studies Near You (Updated 5/25)

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394

Recruiting

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric par... Read More

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires. Read Less

Gender:

ALL

Ages:

Between 6 years and 17 years

Trial Updated:

04/23/2025

Locations: Rehabilitation & Neurological Services /ID# 248517, Huntsville, Alabama +91 locations

Rehabilitation & Neurological Services /ID# 248517, Huntsville, Alabama

Preferred Research Partners /ID# 249729, Little Rock, Arkansas

Preferred Research Partners /ID# 270406, Little Rock, Arkansas

Advanced Research Center /ID# 251381, Anaheim, California

Alliance for Research Alliance for Wellness /ID# 248521, Long Beach, California

Excell Research, Inc /ID# 247532, Oceanside, California

Lumos Clinical Research Center /ID# 249731, San Jose, California

Sunwise Clinical Research /ID# 248529, Walnut Creek, California

Advanced Neurosciences Research, LLC /ID# 247592, Fort Collins, Colorado

Northwest Florida Clinical Research Group, LLC /ID# 251382, Gulf Breeze, Florida

Advanced Research Institute of Miami /ID# 248539, Homestead, Florida

My Preferred Research LLC /ID# 249720, Miami, Florida

Asclepes Research Centers - Spring Hill /ID# 248525, Spring Hill, Florida

Coastal Georgia Child Neurology /ID# 249733, Brunswick, Georgia

Deaconess Clinic - Gateway Health Center /ID# 247589, Newburgh, Indiana

College Park Family Care Center Overland Park /ID# 249734, Overland Park, Kansas

Michigan Headache & Neurological Institute (MHNI) /ID# 247468, Ann Arbor, Michigan

Proven Endpoints LLC /ID# 258066, Ridgeland, Mississippi

Cognitive Clinical Trials (CCT) - Papillion /ID# 248536, Papillion, Nebraska

Goryeb Children's Hospital /ID# 249724, Morristown, New Jersey

Dent Neurologic Institute - Amherst /ID# 248534, Amherst, New York

Modern Migraine MD /ID# 258074, New York, New York

Headache Wellness Center /ID# 251018, Greensboro, North Carolina

Patient Priority Clinical Sites, LLC /ID# 247535, Cincinnati, Ohio

CincyScience /ID# 249726, West Chester, Ohio

Lynn Institute of Oklahoma City /ID# 247600, Oklahoma City, Oklahoma

Le Bonheur Children's Hospital /ID# 261084, Memphis, Tennessee

Access Clinical Trials, Inc. /ID# 248532, Nashville, Tennessee

UT Health Austin at Dell Children's Neurology Clinic /ID# 264082, Austin, Texas

FutureSearch Trials of Neurology /ID# 247470, Austin, Texas

3A Research - East El Paso /ID# 248516, El Paso, Texas

Earle Research /ID# 248501, Friendswood, Texas

Family Psychiatry of The Woodlands /ID# 249727, The Woodlands, Texas

ClinPoint Trials /ID# 248540, Waxahachie, Texas

Pantheon Clinical Research /ID# 251601, Bountiful, Utah

Highland Clinical Research /ID# 247590, Salt Lake City, Utah

Office of Maria Ona /ID# 249738, Franklin, Virginia

Core Clinical Research /ID# 249721, Everett, Washington

Uza /Id# 247339, Edegem, Antwerpen

AZ Sint-Jan Brugge /ID# 247201, Brugge, Not set

Stollery Children's Hospital /ID# 249672, Edmonton, Alberta

London Health Sciences Center- University Hospital /ID# 252979, London, Ontario

Montreal Children's Hospital /ID# 247271, Montreal, Quebec

Herlev Hospital /ID# 247724, Herlev, Hovedstaden

Regionshospitalet Godstrup /ID# 247902, Herning, Midtjylland

Aalborg Sygehus Nord /ID# 247428, Aalborg, Nordjylland

CHU Amiens-Picardie Site Sud /ID# 248833, Amiens CEDEX 1, Somme

Centre Hosp Intercommunal de Creteil /ID# 248832, Creteil, Val-de-Marne

CHU Toulouse - Hôpital des enfants /ID# 247553, Toulouse CEDEX 9, Not set

MIND Clinic /ID# 248687, Budapest, Not set

Semmelweis Egyetem /ID# 248360, Budapest, Not set

Hillel Yaffe Medical Center /ID# 246747, Hadera, H_efa

Bnai Zion Medical Center /ID# 247469, Haifa, H_efa

Shamir Medical Center /ID# 256857, Beer Ya'akov, HaMerkaz

The Chaim Sheba Medical Center /ID# 246746, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 247466, Tel Aviv, Tel-Aviv

Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 247581, Milan, Milano

Ospedale Pediatrico Bambino Gesù /ID# 247647, Rome, Roma

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 247638, Palermo, Not set

Konan Medical Center /ID# 254457, Kobe-shi, Hyogo

Yamaguchi Clinic /ID# 254753, Nishinomiya, Hyogo

Umenotsuji Clinic /ID# 254453, Kochi-shi, Kochi

Sendai Headache and Neurology Clinic Medical Corporation /ID# 254211, Sendai-shi, Miyagi

Tominaga Clinic /ID# 254450, Osaka-shi, Osaka

Tokyo Medical University Hospital /ID# 254459, Shinjuku-ku, Tokyo

Tatsuoka Neurology Clinic /ID# 254455, Kyoto, Not set

Canisius-Wilhelmina Ziekenhuis /ID# 253065, Nijmegen, Gelderland

ZorgSaam Zorggroep Zeeuws-Vlaanderen /ID# 247301, Terneuzen, Zeeland

HagaZiekenhuis /ID# 247318, Den Haag, Zuid-Holland

Athleticomed Sp. z o.o /ID# 248789, Bydgoszcz, Kujawsko-pomorskie

Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 247382, Lublin, Lubelskie

Specjalistyczne Gabinety Sp. z o.o. /ID# 247384, Krakow, Malopolskie

OHA-MED sp. z o.o /ID# 248614, Warszawa, Mazowieckie

Clinical Research Center Sp. z.o.o. Medic-R sp. k /ID# 247383, Poznan, Wielkopolskie

MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 247381, Wroclaw, Not set

Clinical Research Investigator Group, LLC /ID# 261254, Bayamon, Not set

Dr. Samuel Sanchez PSC /ID# 248495, Caguas, Not set

Puerto Rico Health Institute /ID# 249741, Dorado, Not set

Caribbean Medical Research Center /ID# 251634, San Juan, Not set

PRCCI Clinical Research Center /ID# 262726, San Juan, Not set

Spitalul Clinic de Copii Dr. Victor Gomoiu /ID# 248431, Bucharest, Bucuresti

Spitalul Clinic de Urgenta pentru Copii Cluj Napoca /ID# 248595, Cluj-Napoca, Cluj

Delta Health Care S.R.L /ID# 248130, Bucharest, Not set

Hospital Universitario Vall d'Hebron /ID# 247967, Barcelona, Not set

Hospital Clinico San Carlos /ID# 249267, Madrid, Not set

Hospital Universitario Virgen del Rocio /ID# 248632, Sevilla, Not set

Hospital Universitario y Politecnico La Fe /ID# 247969, Valencia, Not set

Sodersjukhuset /ID# 248279, Stockholm, Stockholms Lan

Vastra Gotealandsregionen Regionhalsan /ID# 248277, Molnlycke, Not set

Medway NHS Foundation Trust /ID# 249065, Gillingham, Kent

NHS Grampian /ID# 249067, Aberdeen, Not set

Stockport NHS foundation trust /ID# 261121, Stockport, Not set

Conditions: Episodic Migraine

Register for Updates

Learn More ›

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

NCT05887882

Recruiting

This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (progressive). Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill d... Read More

Gender:

ALL

Ages:

Between 1 year and 38 years

Trial Updated:

04/23/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +3 locations

Conditions: Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Neoplasm

Register for Updates

Learn More ›

Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.

NCT06053567

Recruiting

Anxiety sensitivity, reflecting the fear of bodily sensations, is a risk factor for the maintenance and relapse of smoking. This study is designed to address the question - is a smoking cessation intervention personalized to high anxiety sensitive smokers and adapted for implementation by the YMCA effective among racially/ethnically diverse samples?

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: University of Texas at Austin, Austin, Texas

Conditions: Nicotine Dependence

Register for Updates

Learn More ›

Breath Analysis & Malnutrition

NCT06115148

Recruiting

The purpose of this research study is to understand how breath is related to nutritional status. The procedures involved in this study include blood and breath sampling, questionnaires about health history, medications, nutritional status and diet, and a physical examination. Breath markers will be compared between individuals with and without malnutrition and be compared to indicators of malnutrition. Some individuals will undergo an interventional study involving 2 days of consuming study beve... Read More

Gender:

ALL

Ages:

Between 18 years and 95 years

Trial Updated:

04/23/2025

Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana

Conditions: Malnutrition

Register for Updates

Learn More ›

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009

Recruiting

This study is the first study with TAK-004 conducted in human beings. Participants will receive either TAK-004 or placebo. The main aim of this study is to learn how safe TAK-004 is in healthy adults and how well participants tolerate one or more doses of TAK-004. Other aims are to learn about the effects of TAK-004 on the heart rate and blood pressure and if TAK-004 creates an immune response (immunogenicity). Another aim is to learn how the body of healthy adults affects TAK-004 (pharmacokinet... Read More

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

04/23/2025

Locations: Celerion, Tempe, Arizona

Conditions: Healthy Volunteers

Register for Updates

Learn More ›

Retinal Vascular Changes During Pregnancy

NCT06311617

Recruiting

The goal of this study is to better understand how the back part of the eye-called the retina and the choroid-changes during pregnancy. Specialized photos of the eye will be taken at three different timepoints: early in pregnancy (first or second trimester), late in pregnancy (third trimester), and after delivery. This imaging is non-invasive and does not require contact with the surface of the eye. The photos taken will allow assessment of specific parameters, like blood flow and the health of... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Vanderbilt University Medical Center, Nashville, Tennessee

Conditions: Pregnancy

Register for Updates

Learn More ›

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466

Recruiting

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants.

Gender:

ALL

Ages:

Between 18 years and 50 years

Trial Updated:

04/23/2025

Locations: Research Site, Glendale, California

Conditions: Dilated Cardiomyopathy

Register for Updates

Learn More ›

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

NCT06457919

Recruiting

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

Gender:

MALE

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +10 locations

Conditions: Prostate Cancer

Register for Updates

Learn More ›

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

NCT06550024

Recruiting

An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

Gender:

ALL

Ages:

Between 40 years and 79 years

Trial Updated:

04/23/2025

Locations: University of Alabama Medicine, Birmingham, Alabama +4 locations

Conditions: Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Arthritis, Osteoarthritis

Register for Updates

Learn More ›

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953

Recruiting

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surge... Read More

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects. Read Less

Gender:

ALL

Ages:

21 years and below

Trial Updated:

04/23/2025

Locations: Phoenix Childrens Hospital, Phoenix, Arizona +28 locations

Phoenix Childrens Hospital, Phoenix, Arizona

Arkansas Children's Hospital, Little Rock, Arkansas

Valley Children's Hospital, Madera, California

Kaiser Permanente-Oakland, Oakland, California

Children's Hospital Colorado, Aurora, Colorado

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado

Alfred I duPont Hospital for Children, Wilmington, Delaware

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Nemours Children's Hospital, Orlando, Florida

Riley Hospital for Children, Indianapolis, Indiana

Children's Hospital of Michigan, Detroit, Michigan

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Albany Medical Center, Albany, New York

New York Medical College, Valhalla, New York

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Dayton Children's Hospital, Dayton, Ohio

Oregon Health and Science University, Portland, Oregon

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Saint Jude Children's Research Hospital, Memphis, Tennessee

The Children's Hospital at TriStar Centennial, Nashville, Tennessee

Dell Children's Medical Center of Central Texas, Austin, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

University of Virginia Cancer Center, Charlottesville, Virginia

Seattle Children's Hospital, Seattle, Washington

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington

Conditions: Pleuropulmonary Blastoma

Register for Updates

Learn More ›

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920

Recruiting

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

04/23/2025

Locations: Dent Neurological Institute, Buffalo, New York

Conditions: Generalized Myasthenia Gravis

Register for Updates

Learn More ›

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878

Recruiting

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with RO7790121 in participants with moderately to severely active Crohn's disease (CD).

Gender:

ALL

Ages:

Between 16 years and 80 years

Trial Updated:

04/23/2025

Locations: Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama +45 locations

Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama

Valley View Internal Medicine, Garden Grove, California

Gastro Care Associates, Lancaster, California

Om Research LLC, Lancaster, California

Peak Gastroenterology Surgery Center, Lone Tree, Colorado

Access Research Institute, Brooksville, Florida

Hi Tech and Global Research, LLC, Coral Gables, Florida

Clinical Research of Osceola, LLC, Kissimmee, Florida

Ambert Medical Research, Miami, Florida

Nodal Medical Center Research - NMC, Tampa, Florida

Guardian Angel Research Center, LLC, Tampa, Florida

Theia Clinical Research Centers, LLC, Temple Terrace, Florida

Digestive Healthcare of Georgia, Atlanta, Georgia

Atlanta Gastroenterology Associates, Atlanta, Georgia

Gastroenterology Associates of Central Georgia, Macon, Georgia

Grand Teton Research Group, PLLC, Idaho Falls, Idaho

Illinois Gastroenterology Group-Glenview powered by GI Alliance, Glenview, Illinois

GI Alliance - Gurnee, Gurnee, Illinois

Gastroenterology Health Partners, PLLC, New Albany, Indiana

Kansas Gastroenterology, LLC under Clinical Trials Network, Wichita, Kansas

Tri-State Gastroenterology Associates, Crestview Hills, Kentucky

Gastroenterology Health Partners, PLLC, Louisville, Kentucky

Gastroenterology Associates and Endoscopy Center of North Mississippi, Oxford, Mississippi

Delta Gastroenterology & Endoscopy Center, Southaven, Mississippi

DiGiovanna Inst for Med Ed&Res, North Massapequa, New York

Gastroenterology Group of Rochester under CTNx, Rochester, New York

Monroe Biomedical Research, Monroe, North Carolina

Dayton Gastroenterology, Inc., Beavercreek, Ohio

Ohio Gastroenterology Group, Columbus, Ohio

The Ohio State University Wexner Medical Center, Columbus, Ohio

Gastro Intestinal Research Institute of Northern Ohio, Westlake, Ohio

Central Sooner Research, Norman, Oklahoma

University Gastroenterology, Providence, Rhode Island

Gastro One, Germantown, Tennessee

Quality Medical Research, Nashville, Tennessee

Texas Clinical Research Institute, LLC, Arlington, Texas

Amel Med LLC, Georgetown, Texas

Cano Medical Center, Harlingen, Texas

TDDC dba GI Alliance Research, Mansfield, Texas

Gastroenterology Research of America, LLC, San Antonio, Texas

GI Alliance - Southlake, Southlake, Texas

Tyler Research Institute, LLC, Tyler, Texas

Tidewater Gastroenterology Pllc T/A Gastro. Assoc. of Tidewater, Chesapeake, Virginia

Emeritas Research Group, Lansdowne Town Center, Virginia

Gastroenterology Consultants and Endoscopy Center of Southwest Virginia, Roanoke, Virginia

Wuxi People's Hospital, Wuxi, Not set

Conditions: Moderately to Severely Active Crohns Disease

Register for Updates

Learn More ›

All Clinical Trials

Match to Clinical Trials